Where Global Innovation
and Capital Meet
Sectors Art of CVCConsumerEnergyFinancialHealthIndustrialITMediaServicesStartupsTelecomsTransportUniversity

Page 178

Artiva cleaves $120m in series B round

GC and its GC LabCell subsidiary both contributed to a round that will help advance the cancer immunotherapy developer's NK cell drug pipeline.

Mar 1, 2021

AnchorDX holds down $40m of series C funding

The KingMed Diagnostics and WuXi AppTec-backed cancer diagnosis technology developer intends to use the series C funding to bring its products to market.

Mar 1, 2021

Corporate venturing deal net: 22-26 February 2021

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

Feb 26, 2021

Medisafe gets $30m series C prescription

Sanofi, Merck Group, Qualcomm and Menorah Mivtachim participated in the latest round for the medication management platform developer.

Feb 26, 2021

Cullgen calls in $50m

SIG affiliate Heights Capital Management was among the investors in a series B round for the small molecule therapeutics developer.

Feb 26, 2021

Daily deal net: February 26, 2021

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Feb 26, 2021

SpineZone straightens up with $12m

Funding from investors including Providence Health will allow the musculoskeletal treatment provider to expand its offering and healthcare network.

Feb 26, 2021

Clover discovers $230m in series C funding

The Jinlong Group-backed biologic drug developer’s latest round pushed its overall funding from the past 12 months to approximately $387m.

Feb 26, 2021

Innovaccer vacuums up $105m

Microsoft unit M12 backed the healthcare data software provider in a round that valued the latter at $1.3bn, pushing its overall funding past $225m.

Feb 26, 2021

Lyvgen generates series C funding

IDG Capital has led a round, sized at hundreds of millions of yuan, for the 6 Dimensions Capital-backed cancer therapeutics developer.

Feb 26, 2021
© 2025 Mawsonia Ltd. All rights reserved.
test reg

Login

Not yet subscribed?

See your subscription offers here